What question did this study set out to answer?

This study aims to determine the effects of the crosslink breaker ALT-711 on diabetes-induced cardiac disease.

April 17, 2003Circulation ResearchOpen Access

A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes

View Full Paper

Ask AI

Bookmark

Why the study?

Does ALT-711 attenuate diabetes-induced myocardial structural changes in a rat model of streptozotocin-induced diabetes?

Population

Sprague-Dawley rats with streptozotocin-induced diabetes for 32 weeks

Comparison

ALT-711 (10 mg/kg) initiated at week 16 vs Untreated diabetic rats

Design

Preclinical

Follow-up

32 weeks

Authors

RCRiccardo CandidoUniversity of Trieste JFJosephine M. ForbesTranslational Research Institute MTMerlin C. ThomasSouth Australia Pathology

Discussion

Member takes

Implication

Hypothesis-generating for ALT-711 in diabetic cardiomyopathy; human trials required before any clinical consideration.

Key Points

This study aims to determine the effects of the crosslink breaker ALT-711 on diabetes-induced cardiac disease.
Streptozotocin diabetes was induced in Sprague-Dawley rats for 32 weeks.
ALT-711 (10 mg/kg) treatment started at week 16.
Cardiac parameters and molecular markers were assessed post-treatment.
ALT-711 treatment restored left ventricular collagen solubility and cardiac BNP levels.
The treatment reduced levels of advanced glycation end products (AGEs) and AGE receptors RAGE and AGE-R3.
Collagen III expression and connective tissue growth factor (CTGF) levels were significantly lowered after treatment.

Structured PICO

Does ALT-711 attenuate diabetes-induced myocardial structural changes in a rat model of streptozotocin-induced diabetes?

Population

Sprague-Dawley rats with streptozotocin-induced diabetes for 32 weeks

Intervention

ALT-711 (10 mg/kg) initiated at week 16

Comparator

Untreated diabetic rats

Outcome

Myocardial structural changes including LV collagen solubility, cardiac BNP, AGE levels, RAGE, AGE-R3, CTGF, and collagen III expressionsurrogate

Cleavage of preformed AGE crosslinks with ALT-711 attenuates diabetes-associated cardiac abnormalities in rats, suggesting a potential therapeutic approach for cardiovascular disease in human diabetes.

Cite This Study

Candido et al. (2003) studied this question.

synapsesocial.com/papers/6a120b19ea48cb855a341e11 https://doi.org/10.1161/01.res.0000065620.39919.20

View Full Paper

Ask AI

Bookmark

A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider